Skye Bioscience Inc. (SKYE)
NASDAQ: SKYE
· Real-Time Price · USD
2.45
0.30 (13.95%)
At close: Jun 06, 2025, 3:59 PM
2.42
-1.22%
After-hours: Jun 06, 2025, 05:55 PM EDT
13.95% (1D)
| Bid | 2.34 |
| Market Cap | 75.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.12B |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -2.95 |
| Forward PE | -1.56 |
| Analyst | Buy |
| Ask | 2.47 |
| Volume | 324,540 |
| Avg. Volume (20D) | 702,279 |
| Open | 2.24 |
| Previous Close | 2.15 |
| Day's Range | 2.17 - 2.48 |
| 52-Week Range | 1.14 - 11.20 |
| Beta | 1.67 |
About SKYE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SKYE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SKYE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
+14.97%
Skye Bioscience shares are trading higher after th...
Unlock content with
Pro Subscription
1 month ago
+30.53%
Skye Bioscience shares are trading higher after the company reported weight loss results from its Nimacimab and Tirzepatide preclinical obesity model.
2 weeks ago · proactiveinvestors.co.uk
Arecor shares jump 10% on obesity drug partnership with Skye BioscienceShares in Arecor Therapeutics PLC (AIM:AREC) rose 10% in morning trading after the company announced a new development deal with US biotech group Skye Bioscience to improve the formulation of a mid-st...
2 weeks ago · proactiveinvestors.co.uk
Arecor partners with Skye Bioscience to improve formulation of obesity drugArecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experim...
